This Jazz Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
Avi Kapoor 8 months ago
NewsInitiationMarketsAnalyst RatingsTrading Ideas
Top analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrades, initiations. See what they think of JAZZ stock.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Piper Sandler analyst David Amsellem initiated coverage on Pelthos Therapeutics Inc (AMEX:PTHS) with an Overweight rating and announced a price target of $48. Pelthos Therapeutics shares closed at $23.00 on Thursday. See how other analysts view this stock.
- Barclays analyst Etzer Darout initiated coverage on Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) with an Overweight rating and announced a price target of $224. Jazz Pharmaceuticals shares closed at $188.97 on Thursday. See how other analysts view this stock.
- Rosenblatt analyst John McPeake initiated coverage on Palantir Technologies Inc. (NASDAQ:PLTR) with a Buy rating and announced a price target of $150. Palantir shares closed at $135.94 on Thursday. See how other analysts view this stock.
Considering buying JAZZ stock? Here’s what analysts think:

Photo: Shutterstock
